GE Healthcare advances lung cancer diagnosis with AI

26 November 2021 | News

Joins forces with UK-based Optellum

GE Healthcare and Optellum have signed a letter of intent to collaborate to advance precision diagnosis and treatment of lung cancer.

Optellum's Virtual Nodule Clinic identifies and scores the probability of malignancy in a lung nodule, which is key to determining whether biopsy is necessary, and accelerating diagnosis. It is the only FDA-cleared artificial intelligence (AI)-assisted diagnosis software for early-stage lung cancer, and has been shown to improve the sensitivity and specificity of malignancy assessments of indeterminate nodules, enabling pulmonologists and radiologists to make optimal clinical decisions.

GE plans to collaborate with Optellum's sales team on the distribution of the Virtual Nodule Clinic and work with Optellum to integrate the platform with AI solutions powered by GE Healthcare's Edison platform.

In addition, the companies intend to bring results from Optellum's Lung Cancer Prediction AI into the existing workflow of various GE Healthcare technological pathways, including CT and PACS.